ATE526981T1 - Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen - Google Patents
Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungenInfo
- Publication number
- ATE526981T1 ATE526981T1 AT01947222T AT01947222T ATE526981T1 AT E526981 T1 ATE526981 T1 AT E526981T1 AT 01947222 T AT01947222 T AT 01947222T AT 01947222 T AT01947222 T AT 01947222T AT E526981 T1 ATE526981 T1 AT E526981T1
- Authority
- AT
- Austria
- Prior art keywords
- vegf
- homologues
- neurological disorders
- treat neurological
- disease
- Prior art date
Links
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 102000058223 human VEGFA Human genes 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00201325 | 2000-04-12 | ||
| EP00203382 | 2000-09-29 | ||
| PCT/EP2001/004293 WO2001076620A2 (en) | 2000-04-12 | 2001-04-12 | Use of vegf and homologues to treat neuron disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE526981T1 true ATE526981T1 (de) | 2011-10-15 |
Family
ID=26072122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01947222T ATE526981T1 (de) | 2000-04-12 | 2001-04-12 | Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7226908B2 (de) |
| EP (3) | EP2277528B1 (de) |
| AT (1) | ATE526981T1 (de) |
| AU (2) | AU6896801A (de) |
| CA (3) | CA2659656A1 (de) |
| CY (3) | CY1112126T1 (de) |
| DK (3) | DK1272208T3 (de) |
| ES (3) | ES2551160T3 (de) |
| PT (3) | PT2295070E (de) |
| WO (1) | WO2001076620A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277528B1 (de) * | 2000-04-12 | 2014-11-12 | Vib Vzw | Verwendung von VEGF und Homologen zur Behandlung von neurologischen Störungen |
| US20050026220A1 (en) * | 2001-08-10 | 2005-02-03 | Shahin Rafii | Isolation and mobilization of stem cells expressing vegfr-1 |
| US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
| CN1886149A (zh) * | 2003-09-23 | 2006-12-27 | 路德维格癌症研究院 | Vegf-c或vegf-d物质及刺激神经干细胞的方法 |
| ES2351804T3 (es) * | 2004-05-27 | 2011-02-10 | Vib, Vzw | Tratamiento de esclerosis lateral amiotrófica. |
| US20070021421A1 (en) * | 2005-07-25 | 2007-01-25 | Hampton Thomas G | Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis |
| WO2007023479A2 (en) * | 2005-08-23 | 2007-03-01 | Royal College Of Surgeons In Ireland | Treatment of central nervous system injury |
| CN101534865A (zh) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | 生物活性装配体的制备方法及其用途 |
| GB0803912D0 (en) * | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| ES2376930B1 (es) * | 2009-02-05 | 2013-01-24 | Universidad Del Pais Vasco | Método para el tratamiento de enfermedades neurodegenerativas. |
| ES2622155T3 (es) | 2009-07-24 | 2017-07-05 | Advanced Accelerator Applications S.A. | Compuestos moduladores de la actividad VEGF y usos de los mismos |
| WO2014035433A1 (en) * | 2012-08-31 | 2014-03-06 | Jan Nolta | Genetically modified msc and therapeutic methods |
| US20140065110A1 (en) | 2012-08-31 | 2014-03-06 | The Regents Of The University Of California | Genetically modified msc and therapeutic methods |
| US9663564B2 (en) | 2013-03-15 | 2017-05-30 | The Regents Of The University Of California | Vectors and methods to treat ischemia |
| RU2639175C1 (ru) * | 2016-11-14 | 2017-12-20 | Общество с ограниченной ответственностью "НекстГен" | Способ индукции регенерации периферического нерва |
| WO2019173334A1 (en) | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| WO2019198084A1 (en) * | 2018-04-12 | 2019-10-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-aging compositions and methods of use |
| CN113057142B (zh) * | 2021-03-30 | 2022-12-09 | 四川大学华西医院 | 一种视网膜内和/或视网膜下纤维化动物模型的构建方法 |
| EP4519295A1 (de) * | 2022-05-05 | 2025-03-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3013780A (en) | 1957-12-09 | 1961-12-19 | Shell Oil Co | Gas-liquid contacting apparatus with shutter trays |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US5332671A (en) * | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| DK0751992T3 (da) | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
| ATE281528T1 (de) | 1996-02-21 | 2004-11-15 | Us Gov Health & Human Serv | Rekombinante ribonuklease proteine |
| US6013780A (en) | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
| US5965363A (en) | 1996-09-19 | 1999-10-12 | Genetrace Systems Inc. | Methods of preparing nucleic acids for mass spectrometric analysis |
| SK95599A3 (en) * | 1997-01-17 | 2000-05-16 | Rhone Poulenc Rorer Sa | Adenoviral-vector-mediated gene transfer into medullary motor neurons |
| NZ314594A (en) | 1997-04-14 | 1998-06-26 | Patchett Ag Air Ltd | A spray boom including outlet nozzle clearing means and actuators therefor |
| JP2002505873A (ja) * | 1998-03-13 | 2002-02-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 血管内皮増殖因子2 |
| EP1064382B1 (de) * | 1998-03-17 | 2008-08-20 | Genentech, Inc. | Zu vegf und bmp1 homologe polypeptide |
| CN1319139A (zh) | 1998-09-23 | 2001-10-24 | 牛津生物医学(英国)有限公司 | 多聚核苷酸构建体及其应用 |
| US7125856B1 (en) * | 1999-04-15 | 2006-10-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
| CA2365434A1 (en) | 1999-04-15 | 2000-10-26 | St. Elizabeth's Medical Center Of Boston | Angiogenic growth factors for treatment of peripheral neuropathy |
| WO2001015721A1 (en) * | 1999-08-30 | 2001-03-08 | Sumitomo Pharmaceuticals Company, Limited | Novel uses of semaphorin and vegf |
| US6930089B2 (en) * | 2000-02-04 | 2005-08-16 | D. Collen Research Foundation Vzw | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke |
| EP2277528B1 (de) * | 2000-04-12 | 2014-11-12 | Vib Vzw | Verwendung von VEGF und Homologen zur Behandlung von neurologischen Störungen |
| NZ529915A (en) * | 2001-06-20 | 2007-07-27 | Ludwig Inst Cancer Res | Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186 |
| AU2004209668A1 (en) * | 2003-02-04 | 2004-08-19 | Flanders Interuniversity Institute For Biotechnology | VEGF-B and PDGF modulation of stem cells |
| ES2351804T3 (es) * | 2004-05-27 | 2011-02-10 | Vib, Vzw | Tratamiento de esclerosis lateral amiotrófica. |
-
2001
- 2001-04-12 EP EP10178853.7A patent/EP2277528B1/de not_active Expired - Lifetime
- 2001-04-12 CA CA002659656A patent/CA2659656A1/en not_active Abandoned
- 2001-04-12 DK DK01947222.4T patent/DK1272208T3/da active
- 2001-04-12 PT PT101788107T patent/PT2295070E/pt unknown
- 2001-04-12 DK DK10178810.7T patent/DK2295070T3/en active
- 2001-04-12 EP EP01947222A patent/EP1272208B1/de not_active Expired - Lifetime
- 2001-04-12 ES ES10178810.7T patent/ES2551160T3/es not_active Expired - Lifetime
- 2001-04-12 WO PCT/EP2001/004293 patent/WO2001076620A2/en not_active Ceased
- 2001-04-12 PT PT01947222T patent/PT1272208E/pt unknown
- 2001-04-12 AU AU6896801A patent/AU6896801A/xx active Pending
- 2001-04-12 US US10/257,423 patent/US7226908B2/en not_active Expired - Fee Related
- 2001-04-12 AU AU2001268968A patent/AU2001268968B2/en not_active Ceased
- 2001-04-12 DK DK10178853.7T patent/DK2277528T3/en active
- 2001-04-12 CA CA2654413A patent/CA2654413C/en not_active Expired - Fee Related
- 2001-04-12 ES ES01947222T patent/ES2372809T3/es not_active Expired - Lifetime
- 2001-04-12 ES ES10178853.7T patent/ES2528217T3/es not_active Expired - Lifetime
- 2001-04-12 AT AT01947222T patent/ATE526981T1/de active
- 2001-04-12 PT PT101788537T patent/PT2277528E/pt unknown
- 2001-04-12 EP EP10178810.7A patent/EP2295070B1/de not_active Expired - Lifetime
- 2001-04-12 CA CA002404616A patent/CA2404616C/en not_active Expired - Fee Related
-
2007
- 2007-04-25 US US11/789,703 patent/US20080032314A1/en not_active Abandoned
- 2007-06-04 US US11/810,017 patent/US7592314B2/en not_active Expired - Fee Related
-
2008
- 2008-11-19 US US12/313,338 patent/US7888322B2/en not_active Expired - Fee Related
-
2010
- 2010-12-03 US US12/928,131 patent/US20110288020A1/en not_active Abandoned
-
2011
- 2011-11-30 CY CY20111101176T patent/CY1112126T1/el unknown
-
2015
- 2015-02-10 CY CY20151100131T patent/CY1116296T1/el unknown
- 2015-11-11 CY CY20151101015T patent/CY1116933T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112126T1 (el) | Χρηση toy vegf 165 και των ομολογων για την αγωγη διαταραχων των νευρωνων | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
| ATE380029T1 (de) | Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke | |
| DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
| DE60138019D1 (de) | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung | |
| ATE427114T1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen | |
| DE69111642D1 (de) | Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. | |
| ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| ATE444077T1 (de) | Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| DE60130365D1 (de) | Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen. | |
| ATE335487T1 (de) | Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten | |
| DE69635213D1 (de) | Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen | |
| TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
| MY136718A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| ATE390134T1 (de) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen | |
| BRPI0509559A (pt) | compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos | |
| DE60228988D1 (de) | Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| EP1469730A4 (de) | Verfahren und zusammensetzungen zur behandlung der parkinson-krankheit | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| DE602004013540D1 (de) | Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen | |
| DE60124791D1 (de) | S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen. | |
| DE602004014115D1 (de) | Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1272208 Country of ref document: EP |